Good morning, myeloma world.

We hope your week is getting off to a good start. We've got a couple of new research studies to discuss in today's edition of Myeloma Morning, as well as several highlights from the Beacon's discussion forum.

On the research front, we'll start today by mentioning an article by physicians at the Mayo Clinic's Arizona campus. They report on a com­pli­ca­tion, known as thrombotic microangiopathy (TMA), that occurred in two multiple myeloma patients they had treated with Kyprolis (car­filz­o­mib) (abstract).

TMA is a con­di­tion marked …